Rigel Pharmaceuticals (RIGL) Non-Current Deffered Revenue (2010 - 2020)

Rigel Pharmaceuticals' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $146000.0 for Q3 2020.

• In Q3 2020, Non-Current Deffered Revenue fell 99.42% year-over-year to $146000.0; the TTM figure through Sep 2020 stood at $146000.0 (down 99.42% YoY), while the FY2019 annual figure was $1.4 million, changed 0.28% from the prior year.
• Non-Current Deffered Revenue was $146000.0 for Q3 2020 at Rigel Pharmaceuticals, down from $1.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $26.4 million in Q2 2019 to a low of $90000.0 in Q4 2017.
• Historically, Non-Current Deffered Revenue has averaged $6.3 million across 5 years, with a median of $1.4 million in 2018.
• The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue soared 14720.79% in 2019, then slumped 99.42% in 2020.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $279000.0 in 2016, then plunged by 67.74% to $90000.0 in 2017, then surged by 1464.44% to $1.4 million in 2018, then dropped by 0.28% to $1.4 million in 2019, then plunged by 89.6% to $146000.0 in 2020.
• The last three Non-Current Deffered Revenue figures came in at $146000.0 (Q3 2020), $1.6 million (Q1 2020), and $1.4 million (Q4 2019), per Business Quant data.